Analysis of Risk Factors of Beta-Lactam Drugs Related Acute Kidney Injury in Hospitalized Patients and Developments of Machine Learning Model
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 19,000
- 试验地点
- 1
- 主要终点
- The incidence of acute kidney injury in hospitalized patients treated with β-lactam drugs
研究概览
简要总结
Acute kidney injury (AKI), also known as acute kidney failure (ARF), is a common and complex kidney disease in clinic and an important factor related to poor prognosis of patients in clinic. In the present study, a single-center retrospective study was conducted in our center. The clinical data of hospitalized patients received β-Lactam drugs from January 2018 to December 2020 was retrospectively analyzed. The multiple logistic regression analysis suggested that complicated with hypertension, anemia, pneumonia, shock, sepsis, heart failure, combined use of proton pump inhibitors (PPI), angiotensin-converting enzyme inhibitor (ACEI), angiotensin Ⅱ receptor antagonist (ARB) were independent risk factors for AKI related to β-Lactam drugs. In clinical practice, patients with acute kidney injury risk factors should be closely monitored for changes in their blood creatinine and urine output to avoid acute kidney injury. For patients who have suffered from acute kidney injury, the cause should be removed in time and corresponding symptomatic treatment should be given.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 100 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All inpatients who used β-lactam drugs during hospitalization
- •Hospital stay ≥ 48h
- •Age ≥18 years
- •There are two or more blood creatinine tests during hospitalization
排除标准
- •Hospital stay < 48h
- •Age <18 years
- •Glomerular filtration rate (GFR)< 30ml/min/1.73m2 within 48 hours after admission
- •AKI was diagnosed on admission
- •Less than two Scr test results during hospitalization
- •The Scr values were always lower than 40 μmol/L during hospitalization
- •Cases with incomplete medical history information
研究组 & 干预措施
AKI Group
干预措施: Beta-Lactam Drugs (Drug)
Non-AKI Group
干预措施: Beta-Lactam Drugs (Drug)
结局指标
主要结局
The incidence of acute kidney injury in hospitalized patients treated with β-lactam drugs
时间窗: Through study completion,up to half a year.
To analyze the incidence of acute kidney injury in hospitalized patients after using β-lactam drugs and to build a prediction model.
次要结局
未报告次要终点
研究者
Xiao Li,MD
Associate professor of pharmacy
Qianfoshan Hospital
